German technology company designing and manufacturing viral vectors for cell and gene therapy research and preclinical development.
The company was looking to expand business and operations outside of Germany.
Novoptim allocated 0,25 FTE to promote and sell the products and services in France and Belgium targeting drug discovery and development in pharma and biotech companies.
Novoptim implemented a key account management strategy and developed mapping of Servier, Cellectis, and UCB while building the prospect pipeline. Subsequently, generating revenue of €1.5 million in 3 years.